Alosetron - CAS 122852-42-0
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
Alosetron
Catalog Number:
122852-42-0
Synonyms:
ALOSETRON;ALOSETRON2,3,4,5-Tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one
CAS Number:
122852-42-0
Description:
Alosetron, an effective 5-HT3 receptor antagonist, could be commonly used against irritable bowel syndrome.
Molecular Weight:
294.36
Molecular Formula:
C17H18N4O
Quantity:
Grams-Kilos
COA:
Inquire
MSDS:
Inquire
Canonical SMILES:
CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=CC=CC=C4N3C
InChI:
InChI=1S/C17H18N4O/c1-11-13(19-10-18-11)9-21-8-7-15-16(17(21)22)12-5-3-4-6-14(12)20(15)2/h3-6,10H,7-9H2,1-2H3,(H,18,19)
InChIKey:
JSWZEAMFRNKZNL-UHFFFAOYSA-N
Targets:
5-HT Receptor
Chemical Structure
CAS 122852-42-0 Alosetron

Related 5-HT Receptor Products


CAS 145202-66-0 Rizatriptan Benzoate

Rizatriptan Benzoate
(CAS: 145202-66-0)

Rizatriptan Benzoate is a 5-HT1 agonist triptan drug for the treatment of migraine headaches.

Naronapride
(CAS: 860174-12-5)

Naronapride is a selective 5-HT(4) receptor agonist for gastrointestinal motility disorders. It can accelerate overall colonic transit and tend to accelerate GE...

CAS 442-51-3 Harmine

Harmine
(CAS: 442-51-3)

Harmine induces apoptosis and inhibits proliferation, migration and invasion of human gastric cancer cells, which may be mediated by down-regulation of COX-2 ex...

CAS 181632-25-7 SB 242084

SB 242084
(CAS: 181632-25-7)

SB 242084 is a brain-penetrant antagonist of 5-HT2C receptor which exhibits 158-fold selectivity for 5-HT2C (pKi= 9.0) over 5-HT2A receptor (pKi= 6.1-6.8) and 1...

CAS 111974-69-7 Quetiapine

Quetiapine
(CAS: 111974-69-7)

Quetiapine, an thiazepin-analogue of Clozapine, could be effective in the treatment for schizophrenia and major depressive disorder for behaving as a 5HT-2 and ...

CAS 163521-12-8 Vilazodone

Vilazodone
(CAS: 163521-12-8)

Vilazodone (EMD 68843; SB 659746A) is a combined serotonin specific reuptake inhibitor (SSRI) and 5-HT1A receptor partial agonist currently under clinical evalu...

Aripiprazole lauroxil
(CAS: 1259305-29-7)

Aripiprazole lauroxil is a Dopamine D2 receptor agonist, Serotonin 1A receptor agonist and ISerotonin 2A receptor antagonist under the development of Alkermes p...

CAS 132907-72-3 Ramosetron Hydrochloride

Ramosetron Hydrochloride
(CAS: 132907-72-3)

The hydrochloride salt form of Ramosetron, a benzimidazol derivative, could be used to against nausea and vomiting for acting as a 5-HT3 receptor antagonist.

CAS 170381-16-5 Zicronapine

Zicronapine
(CAS: 170381-16-5)

Zicronapine, an inden derivative, has been found to be neurotransmitter receptor modulators of sorts of neurotransmitter and was studied against Schizophrenia.

CAS 57477-39-1 BRL-54443

BRL-54443
(CAS: 57477-39-1)

BRL 54443 is a 5-HT1E and 5-HT1F receptor agonist with pKi of 8.7 and 9.25, respectively, with a weak binding affinity for 5-HT1A, 5-HT1B, 5-HT1D receptors.

CAS 136765-29-2 Clomipramine D3

Clomipramine D3
(CAS: 136765-29-2)

The isotope labelled form of Clomipramine, an Imipramine derivative, has been found to be a 5-HT Receptor and Dopamine Receptor inhibitor that could be used as ...

CAS 64022-27-1 MK212

MK212
(CAS: 64022-27-1)

MK212 is a 5HT2C-receptor agonist. It exhibited anxiolytic activity in mice at low doses. It is a serotonin agonist. It could promote the secretion of serum pro...

TG6-10-1
(CAS: 1415716-58-3)

TG6-10-1, a potent and selective antagonist for the prostaglandin E2 receptor subtype EP2, has been shown antagonist activity at human EP2 receptor expressed in...

CAS 182349-12-8 Rupatadine Fumarate

Rupatadine Fumarate
(CAS: 182349-12-8)

Rupatadine inhibits both platelet-activating factor (PAF) and histamine (H1) effects through its interaction with specific receptors.

CAS 260779-88-2 Cisapride hydrate

Cisapride hydrate
(CAS: 260779-88-2)

Cisapride, also called as R51619, is a serotonin 5-HT4 receptor agonist used as a gastroprokinetic agent. Cisapride stimulates gastrointestinal motility, probab...

CAS 1977-11-3 Perlapine

Perlapine
(CAS: 1977-11-3)

Perlapine, an atypical neuroleptic, is a potent and selective hM3Dq DREADD agonist (EC50 = 2.8 nM) with >10,000-fold selectivity for hM3Dq over hM3. Perlapine b...

CAS 59729-32-7 Citalopram hydrobromide

Citalopram hydrobromide
(CAS: 59729-32-7)

Citalopram Hydrobromide is an inhibitor of serotonin (5-HT) uptake used as an antidepressant.

CAS 193611-72-2 BRL-15572

BRL-15572
(CAS: 193611-72-2)

BRL-15572 displays high affinity and selectivity for h5-HT1D receptors. BRL-15572 has 60-fold higher affinity for h5-HT1D than 5-HT1B receptors.

CAS 866206-54-4 PRX 08066

PRX 08066
(CAS: 866206-54-4)

PRX 08066, a selective 5-hydroxytryptamine receptor 2B(5-HT2BR) antagonist, causes selective vasodilation of pulmonary arteries. Its IC50 value is 3.4 nM. It ca...

SB-269970
(CAS: 201038-74-6)

SB-269970 is a selective 5-HT7 receptor antagonist (pKi of 8.3) with >50-fold selectivity against other receptors, on amphetamine and ketamine-induced hyperacti...

Reference Reading


1.Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome.
Lacy BE1. Int J Gen Med. 2016 Feb 11;9:7-17. doi: 10.2147/IJGM.S93698. eCollection 2016.
Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders worldwide. The economic impact of IBS on the health care system is substantial, as is the personal impact on patients. Patients with diarrhea-predominant IBS (IBS-D) comprise a substantial proportion of the overall IBS population. Primary care providers are often the first point of contact for patients with IBS-D and can accurately diagnose IBS after a careful history and examination without extensive diagnostic tests. Several pharmacologic treatments (eg, loperamide, alosetron, and antidepressants) and non-pharmacologic treatments (eg, dietary modification and probiotics) are available for IBS-D, but restrictions on use (eg, alosetron) or the lack of controlled trial data showing reductions in both global and individual IBS-D symptoms (eg, bloating, pain and stool frequency) emphasize the need for alternative treatment options. Two newer medications (eluxadoline and rifaximin) were approved in May 2015 for the treatment of IBS-D, and represent new treatment options for this common gastrointestinal condition.
2.Sex-related differences in small intestinal transit and serotonin dynamics in high-fat-diet-induced obesity in mice.
France M1, Skorich E1, Kadrofske M2, Swain GM1,3, Galligan JJ1,4. Exp Physiol. 2016 Jan 1;101(1):81-99. doi: 10.1113/EP085427. Epub 2015 Oct 28.
NEW FINDINGS: What is the central question of this study? Are the sex differences in the effects of obesity on serotonin signaling mechanisms in the small intestine? What is the main finding and its importance? We demonstrate that small intestinal transit is altered in male and female obese mice. We found sex differences in intestinal 5-HT signalling in the jejunum of male and female obese mice that may underlie the altered intestinal transit. Our results reveal important sex differences in 5-HT-linked intestinal dysfunction in obesity. Obesity alters gastrointestinal (GI) motility and 5-HT signalling. Altered 5-HT signalling disrupts control of GI motility. Levels of extracellular 5-HT depend on enterochromaffin (EC) cell release and serotonin transporter (SERT) uptake. We assessed GI transit and 5-HT signalling in the jejunum of normal and obese mice. Male and female mice were fed a control diet (CD; 10% of kilocalories as fat) or a high-fat diet (HFD; 60% of kilocalories as fat).
3.Novel Therapies in IBS-D Treatment.
Nee J1, Zakari M2, Lembo AJ2. Curr Treat Options Gastroenterol. 2015 Dec;13(4):432-40. doi: 10.1007/s11938-015-0068-5.
OPINION STATEMENT: Irritable bowel syndrome (IBS) is a common gastrointestinal disease characterized by abdominal pain and change in bowel habits. IBS diarrhea predominant (IBS-D), which is arguably the most common subset of IBS, is also associated with rectal urgency, increased frequency, abdominal bloating, and loose to watery stools. Current treatments for diarrhea include mu-opioid agonists (i.e., loperamide, lomotil) and bile acid sequestrants (i.e., cholestyramine) while treatments for abdominal pain include antispasmodics (i.e., hyoscyamine, dicyclomine) and tricyclic antidepressants (i.e., amitriptyline). There are currently 3 FDA-approved treatments for IBS-D, which have been shown to improve both abdominal pain and diarrhea. Alosetron was initially approved by FDA 2000; however, its use is now limited to women with severe IBS-D symptoms refractory to other treatment. Eluxadoline, a mixed mu-opioid agonist, and rifaximin, a broad spectrum gut specific antibiotic, were both FDA approved in 2015.
4.Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women.
Fukudo S1, Kinoshita Y2, Okumura T3, Ida M4, Akiho H5, Nakashima Y6, Nishida A7, Haruma K8. Gastroenterology. 2016 Feb;150(2):358-366.e8. doi: 10.1053/j.gastro.2015.10.047. Epub 2015 Nov 6.
BACKGROUND & AIMS: Previous studies have indicated that serotonin-3-receptor antagonists might have a sex-specific effect in patients with irritable bowel syndrome with diarrhea (IBS-D). Alosetron has been approved for the treatment of only women, and ramosetron has been approved for the treatment for only men. We performed a randomized, placebo-controlled, phase 3 study to determine whether ramosetron reduces symptoms of IBS-D in women.